Regulatory

Latest News


Vivus's weight-loss drug Qnexa is heading into an FDA review with the backing of generally positive study data. Will FDA give the thumbs up? Depends on how severe it thinks the side effects are.

Road Map for REMS

FDA's risk-reduction requirements could be the bridge to a bright new future for the pharma industry.

GSK's blockbuster diabetes drug Avandia was the subject of a number of studies this week offering good and bad news. But the company's big challenge is going to be FDA's advisory review panel set to meet in two short weeks.

FDA's meeting on the adoption of REMS for certain prescription opioids doesn't begin until July 22, but the agency's proposal released Tuesday portends a meeting fraught with conflict over the balance between curbing abuse and protecting patient access.

i4-670568-1408636346390.jpg

Pharmaceutical Executive

The Orphan Drug Act of 1983 has been a roaring success. So why is everybody trying to mess with it?

A new Cegedim Dendrite study shows just how ill-equipped pharmaceutical companies are to deal with spending disclosure legislation, and how many are turning to third parties to do the job.

The Indian generic firm Ranbaxy was dealt another blow this week as its version of the enlarged prostate drug Flomax was denied approval in the US just as it was about to go to market.

Pharmaceutical Executive

Pharma companies need a clear online policy that addresses employee obligations, monitoring guidelines, and engagement roles.

i1-661647-1408625788677.jpg

Pharmaceutical Executive

Obligations to fund and support costly studies can extend beyond the period of market exclusivity, giving generics competitors an advantage.

At time when people can't even get a 3 percent cost-of-living increase, how can pharma justify price hikes pushing 500 percent (in some categories). A new study by the government's General Accountability Office examines why drug products took a massive price leap in recent years.

The push for government transparency continues with Phase I of FDA's plan to expose the inner workings of that secretive cabal known as the Food and Drug Association. First up, fancy new FAQs.

Pharmaceutical Executive

The US oversight arm scripted a hefty report complaining that FDA is not moving fast enough when it comes to screening clinical trials data for drugs green lit through its expedited approval program.